Recent Updates
Recently added Catalysts

OraSure Technologies, Inc.

OSURFDA catalysts, PDUFA dates & pipeline intelligence
$3.46
▼ -0.15 · -4.16%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full OSUR financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.2852W HIGH $4.58
Volume
502.80 K
Value Traded
1.76 M
Short % Float
4.05%
Days to Cover
3.6
-4.42%Week
-10.36%1 Month
-10.82%3 Month
-4.16%6 Month
+63.98%1 Year
-63.31%5 Year
+69.88%All Time

Cash Data

Unlock OSUR cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
238.90 M
EPS (TTM)
-0.70
P/E Ratio
-
Ent. Value
90.67 M
Total Shares
69.05 M
Float Shares
64.48 M
Insiders
6.61%
Institutions
83.40%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every OSUR catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

OSUR Catalyst Timeline

Dated clinical, regulatory and corporate events for OraSure Technologies, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for OraSure Technologies, Inc.

791Total events
3Upcoming
180Tier-1 (high impact)
2009 to 2027Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
T2Quarterly Update
Subscribe to view catalyst details

Event history 50

▲Quarterly UpdateCorporate
OraSure reports Q3 2026 financial results with 14% YoY revenue growth
●Quarterly UpdateCorporate
Q2 2026 financial results and earnings call
▲Emergency Use AuthorizationFDA Decision
FDA grants EUA for OraQuick Ebola 2.0 Rapid Antigen Test
Ebola disease (Bundibugyo, Zaire, Sudan, and Taï Forest viruses)source ↗
▲Emergency Use AuthorizationFDA Decision
FDA Emergency Use Authorization for OraQuick™ Ebola 2.0 Rapid Antigen Test
Ebola diseasesource ↗
▼IND WithdrawalIND
Withdrawal of current submission for InteliQuick™ CT/NG molecular self-test
Chlamydia trachomatis and Neisseria gonorrhoeaesource ↗
●Quarterly UpdateCorporate
Q3 2026 revenue guidance provided
▲Product LaunchPost-Market
Q3 commercial launch of OraQuick Ebola 2.0 Rapid Antigen Test with initial orders
Ebola diseasesource ↗
▲Product LaunchColli-Pee™•DxApprovedPost-Market
Q3 commercial launch of Colli-Pee•Dx Urine Collection Kit with initial orders
Sexually transmitted infections (CT, NG, TV, MG)source ↗
▲Product LaunchPost-Market
Q3 commercial launch of OraQuick Ebola 2.0 Rapid Antigen Test with initial orders
Ebola diseasesource ↗
▲Product LaunchPost-Market
Q3 commercial launch of Colli-Pee•Dx Urine Collection Kit with initial orders
Sexually transmitted infections (CT, NG, TV, MG)source ↗
Unlock the full OSUR catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How OSUR actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all OSUR historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
0
Drugs Scored
rNPV / MCap
Top Drug
Top 88%
Micro Cap
(rank 633 of 719)
Percentile Rank
Showing 0 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the OSUR pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every OSUR program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every OSUR trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock OSUR insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Boyd Steven KyleDirectorGrant/Award 3,666 163,234 held$4.43 06/26/2026
Unlock the full OSUR insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SOLEUS CAPITAL MANAGEMENT, L.P. 0.3 % (-88.9 %) 2.14 M 565.00 K -81.51% ( -2.49 M)
Unlock every fund holding OSUR
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in OSUR
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see OSUR ownership
Insider and institutional ownership, quarter by quarter.

OSUR Short Interest

Shares sold short, counted twice a month.

4.05%
Short % of Float
of tradable shares sold short
2.6M
Shares Sold Short
-4.4% vs prior count
3.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
716.7K
Avg Daily Volume
the average used for days to cover
Unlock OSUR short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-12-18
Unlock OSUR option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live OSUR option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock OSUR options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How OSUR ranks across every disease it competes in

Competitive Position is a premium feature
See how OSUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

OSUR News

OSUR
Nov 9, 2026
OSURGeneral
▼ -5.7%on this news

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion

OraSure Technologies reported a 14% increase in revenue for Q3 2026, reaching $30.9 million. The company's gross margin improved to 45.2%, reflecting operational efficiencies. New products, including the Colli-Pee®Dx and OraQuick® Ebola 2.0, saw initial orders. Looking ahead, OraSure anticipates continued revenue growth into 2027.

Read more →
OSUR
Nov 2, 2026
OSURGeneral
▼ -12.3%on this news

OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care

OraSure Technologies has joined the World Coalition on Sickle Cell Disease to enhance global efforts in early diagnosis and care for sickle cell disease. The Coalition aims to elevate the condition on the health agenda and improve services for affected individuals. OraSure will contribute its diagnostic expertise to strengthen connections between diagnosis and treatment.

Read more →
OSUR
Oct 26, 2026
OSURConferences/Events

OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th

OraSure Technologies, Inc. will announce its third quarter 2026 financial results on November 9, 2026, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss these results. A webcast of the call will be available on their investor relations page.

Read more →
OSUR
Aug 5, 2026
OSURGeneral

OraSure Announces Second Quarter 2026 Financial Results

OraSure Technologies reported its Q2 2026 financial results, showing a 9.7% sequential revenue increase to $30.6 million. The company achieved FDA clearance for its Colli-Pee™•Dx urine collection device and received Emergency Use Authorization for the OraQuick™ Ebola 2.0 Rapid Antigen Test. Despite these advancements, total revenues decreased by 2% year-over-year, and the company recorded a non-GAAP operating loss.

Read more →
OSUR
Jul 22, 2026
OSURConferences/Events
▲ +6.3%on this news

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OraSure Technologies, Inc. will announce its second quarter 2026 financial results on August 5, 2026, after market close. The company will host a conference call at 5 p.m. Eastern Time to discuss these results. A webcast of the call will be available on their investor relations page and archived for one year.

Read more →
OSUR
Jul 21, 2026
OSURFDA Updates

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OraSure Technologies received Emergency Use Authorization for its second-generation OraQuick™ Ebola 2.0 Rapid Antigen Test. This test can detect all four Ebola viruses and is designed for use with both live patients and deceased individuals. The FDA authorization comes amid a significant outbreak in Central Africa, highlighting the urgent need for effective diagnostics.

Read more →
OSUR
Jun 11, 2026
OSURFDA Updates

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, enabling at-home self-collection for STI testing. This advancement allows for convenient sample collection while maintaining sample integrity. The kit supports Roche's molecular diagnostic systems and aims to improve access for underserved populations, facilitating scalable testing and public health initiatives.

Read more →
OSUR
May 7, 2026
OSURGeneral

OraSure Announces First Quarter 2026 Financial Results

OraSure Technologies, Inc. reported a revenue of $27.9 million for Q1 2026, surpassing its guidance midpoint. The company highlighted gross margin expansion and a strong balance sheet, which positions it well for growth and potential acquisitions. OraSure aims to decentralize diagnostics to improve healthcare accessibility and affordability.

Read more →
OSUR
May 6, 2026
OSURGeneral

OraSure Technologies, Inc. 2OTI Proprietary Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the "Company" or "OraSure") contains certain "forward-looking statements" within the me

OraSure Technologies, Inc. has provided an investor update discussing its transformation strategy and financial performance. In Q1, the company reported a 4% growth in total revenue, demonstrating positive traction in its core business segments. The update highlights key operational improvements, including a focus on disciplined execution and the return to breakeven for its core business. Additionally, there is an optimistic outlook for growth driven by innovation and improved visibility into funding for critical testing programs.

Read more →
OSUR
Apr 22, 2026
OSURGeneral

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies, Inc. will announce its first quarter 2026 financial results during an earnings call scheduled for May 6, 2026. The call will take place at 5 p.m. ET and will be accessible via a webcast on the company's investor relations page. This event is part of OraSure's commitment to transparency and stakeholder engagement.

Read more →
OSUR
Apr 17, 2026
OSURGeneral

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Technologies has appointed John D. Bertrand as an independent director to its Board of Directors. His extensive experience in healthcare technology and AI-enabled diagnostics is expected to bolster the company's strategic initiatives. Additionally, OraSure plans to seek shareholder approval to declassify its Board at the upcoming 2026 Annual Meeting, reflecting its commitment to governance and shareholder engagement.

Read more →
OSUR
Mar 30, 2026
OSURGeneral

Strategy & Growth Outlook OraSure is executing a focused strategy with near-term catalysts expected to drive revenue growth, margin expansion, and profitability Public health funding environment stabilizing across U.S. a

OraSure is actively pursuing a focused strategy designed to enhance revenue growth and profitability, with several product launches on the horizon. The company's diagnostics segment is poised for expansion, leveraging existing infrastructures and improving efficiency through operational transitions. Despite facing challenges, including pressure from Altai Capital regarding board decisions, OraSure aims for a strong market position as health funding stabilizes and testing volumes recover post-2025.

Read more →
OSUR
Mar 18, 2026
OSURGeneral

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OraSure Technologies, Inc. is responding to Altai Capital's demands for board representation, emphasizing its commitment to shareholder value and upcoming milestones in 2026. The company has engaged extensively with Altai but has faced rejection of settlement proposals. OraSure's Board has been refreshed with new independent directors to guide the company through this critical phase.

Read more →
OSUR
Feb 26, 2026
OSURGeneral
▲ +10%on this news

OraSure Announces Fourth Quarter 2025 Financial Results

OraSure Technologies reported its Q4 2025 financial results, achieving revenue of $26.8 million, which surpassed expectations. The company is optimistic about growth in 2026, driven by anticipated regulatory clearances and new product launches. OraSure's CEO highlighted the stability in key segments and the company's strategic investments to enhance value.

Read more →
OSUR
Feb 10, 2026
OSURGeneral

OraSure to Launch OraQuick™ HIV Self-Test in Canada

OraSure Technologies has announced that its OraQuick HIV Self-Test has received licensing from Health Canada, making it the first oral HIV self-test available in Canada. The test allows individuals to determine their HIV status using a simple oral swab in just 20 minutes. This initiative aims to improve access to HIV testing and support public health efforts in combating the epidemic.

Read more →
OSUR
Feb 10, 2026
OSURConferences/Events

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

OraSure Technologies, Inc. will hold its earnings conference call on February 25, 2026, at 5 p.m. ET to discuss its fourth quarter 2025 financial results and business developments. The call will be accessible via a webcast on the company's investor relations page, which will also archive the session afterward.

Read more →
OSUR
Jan 15, 2026
OSURGeneral

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

OraSure Technologies has confirmed the receipt of director nominations from Altai Capital for the upcoming 2026 Annual Meeting of Stockholders. The nominations include Altai's founder, Rishi Bajaj. However, since interviewing Mr. Bajaj, OraSure's Board has appointed alternative candidates and has not engaged further with Altai. The Board has seen a significant refreshment with seven departures and three new independent members, aiming to enhance its oversight of growth and value creation.

Read more →
OSUR
Jan 5, 2026
OSURFDA Updates

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

OraSure Technologies has submitted applications to the FDA for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, alongside its Colli-Pee™ urine collection device. These submissions aim to enhance accessibility and convenience in STI testing. The company anticipates significant market opportunities, although regulatory approvals and competition pose potential risks.

Read more →
OSUR
Dec 17, 2025
OSURGeneral

OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates

OraSure Technologies has confirmed the intent of Altai Capital to nominate two candidates for election to its Board of Directors at the 2026 Annual Meeting. The company maintains a commitment to shareholder value and has engaged in dialogue with Altai, evaluating its founder, Rishi Bajaj, for board service. Despite not appointing him, OraSure has made efforts to enhance its Board and is actively pursuing innovation in diagnostics. The company remains well-positioned financially with substantial cash reserves and no debt as it strives for sustainable profitability.

Read more →

About OraSure Technologies, Inc.

Bethlehem, PA 500 employees orasure.com
Headquarters220 E FIRST ST, BETHLEHEM, PA, 18015
BIOPHARMAWATCH ELITE
Trade the next OSUR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime